NCT ID | NCT03033914 |
Title | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma |
Recruitment | Recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | no |
Sponsors | Memorial Sloan Kettering Cancer Center |
Indications | |
Therapies |
Dacarbazine + Doxorubicin + Vinblastine + Nivolumab Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab |
Age Groups: | adult senior |